Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion
Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis...
Gespeichert in:
Veröffentlicht in: | Chest 2012-08, Vol.142 (2), p.394-400 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 400 |
---|---|
container_issue | 2 |
container_start_page | 394 |
container_title | Chest |
container_volume | 142 |
creator | Fysh, Edward T.H., MBBS Waterer, Grant W., PhD Kendall, Peter A., MBBS Bremner, Peter R., MBChB Dina, Sharifa, RN Geelhoed, Elizabeth, PhD McCarney, Kate, RN Morey, Sue, NP Millward, Michael, MA Musk, A.W. (Bill), MD, FCCP Lee, Y.C. Gary, PhD, FCCP |
description | Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable. |
doi_str_mv | 10.1378/chest.11-2657 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1095631499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0012369212604528</els_id><sourcerecordid>1095631499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</originalsourceid><addsrcrecordid>eNpFkU1r3DAQhkVoaTZpj7kWXwq5ONVIlmxdCmXztZCS0o-zkKVxotQrbyQ7Yf995eymPQ0Dz7zMPEPICdAz4HXz2d5jGs8ASiZFfUAWoDiUXFT8DVlQCqzkUrFDcpTSA809KPmOHDJWUakkXZB2Fdwz9r0Pd8X3Hqdo-mJpxnscMabiB7rJYrEKGzN6DGNxbrapuH3CuIMHh8mnohti8c30_i6YzLzGXHTdlPwQ3pO3nekTftjXY_L78uLX8rq8ub1aLb_elLaqqrEEKmonWsk56xTPpwnBHXSmlkI0jXEtk0ZIbKVUjbWsReY4CgdAK8uFYPyYnO5yN3F4nLIVvfbJ5ttMwGFKGqgSkkOlVEbLHWrjkFLETm-iX5u4zZCeteoXrRpAz1oz_3EfPbVrdP_oV48Z-LQHTLKm76IJ1qf_nGSM1vW845cdh1nEk8eobVbv88gf3GJ6GKYYsiMNOjFN9c_5g_MDgUlaCdbwvySLlW0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1095631499</pqid></control><display><type>article</type><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</creator><creatorcontrib>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><description>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.11-2657</identifier><identifier>PMID: 22406960</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: American College of Chest Physicians</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Cardiology. Vascular system ; Catheters, Indwelling ; Drainage - instrumentation ; Female ; Follow-Up Studies ; Humans ; Length of Stay ; Male ; Medical sciences ; Patient Preference ; Pilot Projects ; Pleural Effusion, Malignant - complications ; Pleural Effusion, Malignant - pathology ; Pleural Effusion, Malignant - therapy ; Pleurodesis ; Pneumology ; Prospective Studies ; Pulmonary/Respiratory ; Talc - administration & dosage ; Treatment Outcome ; Tumors of the respiratory system and mediastinum</subject><ispartof>Chest, 2012-08, Vol.142 (2), p.394-400</ispartof><rights>The American College of Chest Physicians</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</citedby><cites>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26220772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22406960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fysh, Edward T.H., MBBS</creatorcontrib><creatorcontrib>Waterer, Grant W., PhD</creatorcontrib><creatorcontrib>Kendall, Peter A., MBBS</creatorcontrib><creatorcontrib>Bremner, Peter R., MBChB</creatorcontrib><creatorcontrib>Dina, Sharifa, RN</creatorcontrib><creatorcontrib>Geelhoed, Elizabeth, PhD</creatorcontrib><creatorcontrib>McCarney, Kate, RN</creatorcontrib><creatorcontrib>Morey, Sue, NP</creatorcontrib><creatorcontrib>Millward, Michael, MA</creatorcontrib><creatorcontrib>Musk, A.W. (Bill), MD, FCCP</creatorcontrib><creatorcontrib>Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><title>Chest</title><addtitle>Chest</addtitle><description>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Catheters, Indwelling</subject><subject>Drainage - instrumentation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patient Preference</subject><subject>Pilot Projects</subject><subject>Pleural Effusion, Malignant - complications</subject><subject>Pleural Effusion, Malignant - pathology</subject><subject>Pleural Effusion, Malignant - therapy</subject><subject>Pleurodesis</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Pulmonary/Respiratory</subject><subject>Talc - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1r3DAQhkVoaTZpj7kWXwq5ONVIlmxdCmXztZCS0o-zkKVxotQrbyQ7Yf995eymPQ0Dz7zMPEPICdAz4HXz2d5jGs8ASiZFfUAWoDiUXFT8DVlQCqzkUrFDcpTSA809KPmOHDJWUakkXZB2Fdwz9r0Pd8X3Hqdo-mJpxnscMabiB7rJYrEKGzN6DGNxbrapuH3CuIMHh8mnohti8c30_i6YzLzGXHTdlPwQ3pO3nekTftjXY_L78uLX8rq8ub1aLb_elLaqqrEEKmonWsk56xTPpwnBHXSmlkI0jXEtk0ZIbKVUjbWsReY4CgdAK8uFYPyYnO5yN3F4nLIVvfbJ5ttMwGFKGqgSkkOlVEbLHWrjkFLETm-iX5u4zZCeteoXrRpAz1oz_3EfPbVrdP_oV48Z-LQHTLKm76IJ1qf_nGSM1vW845cdh1nEk8eobVbv88gf3GJ6GKYYsiMNOjFN9c_5g_MDgUlaCdbwvySLlW0</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Fysh, Edward T.H., MBBS</creator><creator>Waterer, Grant W., PhD</creator><creator>Kendall, Peter A., MBBS</creator><creator>Bremner, Peter R., MBChB</creator><creator>Dina, Sharifa, RN</creator><creator>Geelhoed, Elizabeth, PhD</creator><creator>McCarney, Kate, RN</creator><creator>Morey, Sue, NP</creator><creator>Millward, Michael, MA</creator><creator>Musk, A.W. (Bill), MD, FCCP</creator><creator>Lee, Y.C. Gary, PhD, FCCP</creator><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><author>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Catheters, Indwelling</topic><topic>Drainage - instrumentation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patient Preference</topic><topic>Pilot Projects</topic><topic>Pleural Effusion, Malignant - complications</topic><topic>Pleural Effusion, Malignant - pathology</topic><topic>Pleural Effusion, Malignant - therapy</topic><topic>Pleurodesis</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Pulmonary/Respiratory</topic><topic>Talc - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fysh, Edward T.H., MBBS</creatorcontrib><creatorcontrib>Waterer, Grant W., PhD</creatorcontrib><creatorcontrib>Kendall, Peter A., MBBS</creatorcontrib><creatorcontrib>Bremner, Peter R., MBChB</creatorcontrib><creatorcontrib>Dina, Sharifa, RN</creatorcontrib><creatorcontrib>Geelhoed, Elizabeth, PhD</creatorcontrib><creatorcontrib>McCarney, Kate, RN</creatorcontrib><creatorcontrib>Morey, Sue, NP</creatorcontrib><creatorcontrib>Millward, Michael, MA</creatorcontrib><creatorcontrib>Musk, A.W. (Bill), MD, FCCP</creatorcontrib><creatorcontrib>Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fysh, Edward T.H., MBBS</au><au>Waterer, Grant W., PhD</au><au>Kendall, Peter A., MBBS</au><au>Bremner, Peter R., MBChB</au><au>Dina, Sharifa, RN</au><au>Geelhoed, Elizabeth, PhD</au><au>McCarney, Kate, RN</au><au>Morey, Sue, NP</au><au>Millward, Michael, MA</au><au>Musk, A.W. (Bill), MD, FCCP</au><au>Lee, Y.C. Gary, PhD, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>142</volume><issue>2</issue><spage>394</spage><epage>400</epage><pages>394-400</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</abstract><cop>Northbrook, IL</cop><pub>American College of Chest Physicians</pub><pmid>22406960</pmid><doi>10.1378/chest.11-2657</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-3692 |
ispartof | Chest, 2012-08, Vol.142 (2), p.394-400 |
issn | 0012-3692 1931-3543 |
language | eng |
recordid | cdi_proquest_miscellaneous_1095631499 |
source | MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Aged Aged, 80 and over Biological and medical sciences Cardiology. Vascular system Catheters, Indwelling Drainage - instrumentation Female Follow-Up Studies Humans Length of Stay Male Medical sciences Patient Preference Pilot Projects Pleural Effusion, Malignant - complications Pleural Effusion, Malignant - pathology Pleural Effusion, Malignant - therapy Pleurodesis Pneumology Prospective Studies Pulmonary/Respiratory Talc - administration & dosage Treatment Outcome Tumors of the respiratory system and mediastinum |
title | Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Indwelling%20Pleural%20Catheters%20Reduce%20Inpatient%20Days%20Over%20Pleurodesis%20for%20Malignant%20Pleural%20Effusion&rft.jtitle=Chest&rft.au=Fysh,%20Edward%20T.H.,%20MBBS&rft.date=2012-08-01&rft.volume=142&rft.issue=2&rft.spage=394&rft.epage=400&rft.pages=394-400&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.11-2657&rft_dat=%3Cproquest_cross%3E1095631499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1095631499&rft_id=info:pmid/22406960&rft_els_id=1_s2_0_S0012369212604528&rfr_iscdi=true |